Summit Therapeutics (SMMT) Non-Current Assets: 2016-2025
Historic Non-Current Assets for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $15.3 million.
- Summit Therapeutics' Non-Current Assets rose 21.50% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 21.50%. This contributed to the annual value of $11.8 million for FY2024, which is 10.78% down from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Non-Current Assets is $15.3 million, which was up 3.15% from $14.8 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Non-Current Assets registered a high of $26.5 million during Q3 2021, and its lowest value of $6.9 million during Q1 2023.
- In the last 3 years, Summit Therapeutics' Non-Current Assets had a median value of $13.1 million in 2025 and averaged $12.5 million.
- As far as peak fluctuations go, Summit Therapeutics' Non-Current Assets slumped by 59.68% in 2023, and later soared by 96.74% in 2024.
- Quarterly analysis of 5 years shows Summit Therapeutics' Non-Current Assets stood at $16.1 million in 2021, then tumbled by 53.58% to $7.5 million in 2022, then spiked by 77.53% to $13.2 million in 2023, then declined by 10.78% to $11.8 million in 2024, then climbed by 21.50% to $15.3 million in 2025.
- Its last three reported values are $15.3 million in Q3 2025, $14.8 million for Q2 2025, and $13.1 million during Q1 2025.